Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence
Langerhans Cell Histiocytosis of Bone

About this trial
This is an interventional treatment trial for Langerhans Cell Histiocytosis of Bone focused on measuring Langerhans cell histiocytosis, Bone, Single-system, Children, Adolescents
Eligibility Criteria
Inclusion Criteria: Pathological diagnosis of Langerhans cell histiocytosis (LCH) of bone; Single-system involvement (skeletal system); No need of surgical intervention; Must be able to swallow tablets; Signing informed consent form. Exclusion Criteria: Multi-system involvements (≥2 systems, including bone, liver, spleen, hematologic system, central nerve system); Need of surgical intervention (e.g. pathological fracture and/or spinal cord compression) Glucocorticoid allergy; Immunodeficiency; Severe infection; Insulin dependent/independent Diabetes; Having taken glucocorticoid in the past two weeks; Not capable of swallowing tablets; Without signed informed consent inform.
Sites / Locations
- Shanghai Changzheng HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Oral prednisone
Regular observation
Oral prednisone, 0.5mg/kg/day, first 5 days/month, 6months
Regular observation and follow up without medication